Enanta Pharmaceuticals Inc.

50.86-0.9000-1.74%Vol 19.64K1Y Perf -5.28%
Apr 16th, 2021 11:19 DELAYED
BID50.64 ASK50.86
Open52.03 Previous Close51.76
Pre-Market- After-Market-
 - -%  - -
Target Price
68.00 
Analyst Rating
Hold 2.60
Potential %
33.23 
Finscreener Ranking
★★★+     52.57
Insiders Trans % 3/6/12 mo.
-/-100/-100 
Value Ranking
★★★★+     58.73
Insiders Value % 3/6/12 mo.
-/-100/-100 
Growth Ranking
★★+     49.41
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-100 
Income Ranking
 —    -
Market Cap1.03B 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
57.69 
Earnings Date
5th May 2021

Today's Price Range

50.6752.45

52W Range

40.3258.59

5 Year PE Ratio Range

4.10138.90

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
6.17%
1 Month
-1.20%
3 Months
10.79%
6 Months
15.72%
1 Year
-5.28%
3 Years
-39.78%
5 Years
64.37%
10 Years
-

TickerPriceChg.Chg.%
ENTA50.86-0.9000-1.74
AAPL133.90-0.6000-0.45
GOOG2 294.67-1.9900-0.09
MSFT259.540.04000.02
XOM56.980.00000.00
WFC43.090.85002.01
JNJ161.220.83000.52
FB305.81-2.0100-0.65
GE13.46-0.0900-0.66
JPM153.171.00000.66
Financial StrengthValueIndustryS&P 500US Markets
18.10
19.40
0.01
0.02
-
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
-
-65.70
-62.20
20.40
-76.96
RevenueValueIndustryS&P 500US Markets
74.03M
3.67
-15.12
9.94
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.82-0.4150.00
Q04 2020-0.92-0.5540.22
Q03 2020-0.73-0.712.74
Q02 2020-0.73-0.3058.90
Q01 20200.590.6510.17
Q04 20190.570.44-22.81
Q03 20190.070.33371.43
Q02 2019-0.090.20322.22
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.9321.19Positive
6/2021 QR-1.0017.36Positive
9/2021 FY-3.2024.71Positive
9/2022 FY-4.8019.87Positive
Next Report Date5th May 2021
Estimated EPS Next Report-0.93
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume19.64K
Shares Outstanding20.17M
Trades Count449
Dollar Volume5.93M
Avg. Volume149.31K
Avg. Weekly Volume88.39K
Avg. Monthly Volume127.41K
Avg. Quarterly Volume148.90K

Enanta Pharmaceuticals Inc. (NASDAQ: ENTA) stock closed at 51.76 per share at the end of the most recent trading day (a 2.19% change compared to the prior day closing price) with a volume of 111.03K shares and market capitalization of 1.03B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 141 people. Enanta Pharmaceuticals Inc. CEO is Jay R. Luly.

The one-year performance of Enanta Pharmaceuticals Inc. stock is -5.28%, while year-to-date (YTD) performance is 22.95%. ENTA stock has a five-year performance of 64.37%. Its 52-week range is between 40.32 and 58.59, which gives ENTA stock a 52-week price range ratio of 57.69%

Enanta Pharmaceuticals Inc. currently has a PE ratio of -17.10, a price-to-book (PB) ratio of 2.20, a price-to-sale (PS) ratio of 13.21, a price to cashflow ratio of 154.60, a PEG ratio of 2.32, a ROA of -11.17%, a ROC of -12.17% and a ROE of -11.86%. The company’s profit margin is -76.96%, its EBITDA margin is -62.20%, and its revenue ttm is $74.03 Million , which makes it $3.67 revenue per share.

Of the last four earnings reports from Enanta Pharmaceuticals Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.93 for the next earnings report. Enanta Pharmaceuticals Inc.’s next earnings report date is 05th May 2021.

The consensus rating of Wall Street analysts for Enanta Pharmaceuticals Inc. is Hold (2.6), with a target price of $68, which is +33.23% compared to the current price. The earnings rating for Enanta Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Enanta Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Enanta Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 7.61, ATR14 : 2.34, CCI20 : 115.34, Chaikin Money Flow : -0.10, MACD : 0.12, Money Flow Index : 55.53, ROC : 5.03, RSI : 62.91, STOCH (14,3) : 77.80, STOCH RSI : 1.00, UO : 56.81, Williams %R : -22.20), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Enanta Pharmaceuticals Inc. in the last 12-months were: Jay R. Luly (Option Excercise at a value of $0), Nathalie Adda (Option Excercise at a value of $0), Nathaniel S. Gardiner (Option Excercise at a value of $99 990), Paul J. Mellett (Option Excercise at a value of $10 949), Paul J. Mellett (Sold 6 000 shares of value $273 463 ), Yat Sun Or (Option Excercise at a value of $173 576)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (40.00 %)
2 (40.00 %)
2 (33.33 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (40.00 %)
2 (40.00 %)
3 (50.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (20.00 %)
1 (20.00 %)
1 (16.67 %)
Summary RatingHold
2.60
Hold
2.60
Hold
2.67

Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

CEO: Jay R. Luly

Telephone: +1 617 607-0800

Address: 500 Arsenal Street, Watertown 02472, MA, US

Number of employees: 141

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

67%33%

Bearish Bullish

57%43%

Bearish Bullish

45%55%

News

Stocktwits